Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

Financing Activities15,125,489-Net Change in Cash and Cash Equivalents3,370,543-Cash and Cash Equivalents – Beginning of Period3,924,908112Cash and Cash Equivalents – End of Period$7,295,451$112Supplemental Disclosures of Cash Flow Information and Non-cash Transactions:Interest Paid$14,460$-SOURCE Citius Oncology, Inc.## 21%[more press release views with Request a Demo]## Also from this source### Citius Oncology Expands International Distribution of LYMPHIRâ"¢ to European Union Through Exclusive Agreement w ...